Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007 |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qPCR, luciferase reporter assay etc. |
| Sample | cell line (PBMCs) |
| Expression Pattern | up-regulated |
| Function Description | Meanwhile, GAS5 is downregulated in breast cancer cells.Survival analysis indicated that GAS5 rs55829688 (T > C) was significantly associated with prognosis of AML (p=0.018).Patients with rs55829688 CC genotype showed higher GAS5 expression in peripheral blood mononuclear cells (PBMCs) (p=0.025) and harbored a longer platelets recovery (p=0.040) than carriers of rs55829688T allele. In conclusion, rs55829688 polymorphism could increase GAS5 expression by interacting with TP63, which might aggravate the myelosuppression and in turn lead to poor prognosis in AML. GAS5 is observed to be a key mediator of glucocorticoids (GCs) resistance rather than a growth arrest-specific transcript in PBMCs. |
| Pubmed ID | 27951730 |
| Year | 2017 |
| Title | Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution. |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for myeloid leukemia | OMIM COSMIC |